

30 November 2023

Negotiation ongoing for Osteopore and InnoVentures to enter Definitive JV Agreement

Australian-Singaporean medical technology company **Osteopore Limited (ASX:OSX; Osteopore or Company)** previously announced on 12 September 2023, the signing of a Memorandum of Understanding with China-based medical device innovation accelerator InnoVentures Inc (**InnoVentures**), to enter a joint venture (**JV**) agreement aimed at commercialising Osteopore's orthopaedic products in China. A definitive agreement pertaining to the JV was to be executed by 30 November 2023, however negotiations are currently ongoing and the Company will continue to keep the market updated on any material development in relation to this definitive agreement.

ENDS

This announcement dated 30 November 2023 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

T: +65 9011 7009

E: mark_leong@osteopore.com**Isaac Stewart**

Media & Investor Relations

Cannings Purple

T: +61 423 306 795

E: istewart@canningspurple.com.au

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are or may be, forward-looking statements.

Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Depending on various factors, actual results may differ materially from those expressed or implied by these forward-looking statements.

